Celldex Therapeutics Inc Recap

What is your opinion of Celldex Therapeutics Inc?

Celldex Therapeutics Inc

NASDAQ:CLDX - May. 30th 12:09am

$ 28.87 -0.16 (-0.55%)

Shares of Celldex Therapeutics Inc – a $2.6 billion market cap Pharmaceuticals company – have fallen -0.55 percent to $28.87 as of 9:42 PM. With the current share price, Celldex Therapeutics Inc has a P/E Ratio of 0.00.

Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.

Find out more about Celldex Therapeutics Inc.


Celldex Therapeutics Inc Hit a 52-week High

Celldex Therapeutics Inc (NASDAQ:CLDX) hit a 52-week share price high of $32.82.

HAMPTON, NJ | 2 months ago

Financials
Celldex Therapeutics Inc